Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER vs AMINO ACIDS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Travasol 4.25% in Dextrose 15% is a combination of amino acids and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis, while dextrose provides a source of calories. The mechanism involves intravenous administration bypassing the gastrointestinal tract to deliver nutrients directly into the bloodstream, supporting tissue repair, growth, and metabolic functions.
Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.
Parenteral nutrition for patients unable to obtain adequate nutrition orally or enterally,Adjunct to oral or enteral nutrition when intake is insufficient,Metabolic support in catabolic states such as major surgery, trauma, or burns
Total parenteral nutrition (TPN) for patients unable to ingest or absorb adequate nutrients,Supplementation in metabolic disorders (e.g., urea cycle disorders, maple syrup urine disease),Treatment of negative nitrogen balance due to trauma, burns, or surgery
Intravenous infusion; typical adult dose is 500 m L to 1000 m L per day, administered at a rate of 200 m L/hour, adjusted based on metabolic and fluid needs.
1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.
Not applicable as a single entity; components have intrinsic half-lives. Amino acids: rapid distribution (minutes), with terminal elimination of metabolites (e.g., urea) ~4-8 hours. Dextrose: half-life ~1-2 hours in steady state.
Variable; endogenous amino acids: 10–30 min for clearance from plasma; administered doses: distribution half-life ~5–10 min, terminal elimination half-life ~15–30 min, reflecting rapid metabolic utilization and renal reabsorption.
The amino acids in Travasol are metabolized via various pathways including transamination, deamination, and urea cycle in the liver and other tissues. Dextrose undergoes glycolysis and oxidative phosphorylation to produce ATP.
Amino acids are metabolized primarily in the liver via transamination, deamination, and urea cycle. Specific pathways exist for each amino acid; excess nitrogen is converted to urea.
TRAVASOL 4.25% IN DEXTROSE 15% (amino acids and dextrose) is a parenteral nutrition solution. Amino acids are metabolized to urea, which is excreted renally; dextrose is metabolized to CO2 and water. No significant biliary/fecal elimination.
Renal: >95% as amino acids and metabolites, primarily reabsorbed; <5% unchanged. Fecal/biliary: negligible (<1%).
Amino acids: minimal to no protein binding (<10%). Dextrose: not protein bound.
Minimal for most amino acids (<10%); albumin and globulins bind tryptophan and aromatic amino acids (~80–90% for tryptophan).
Total body water distribution: ~0.55 L/kg for amino acids; dextrose distributes in extracellular fluid (~0.2 L/kg).
0.4–0.6 L/kg (total body water); reflects equilibration with intracellular and extracellular fluid compartments.
IV: 100% bioavailability; not administered orally or via other routes.
Oral: ~90–100% (active transport across intestinal mucosa); IV: 100%.
In acute kidney injury or chronic kidney disease with GFR <30 m L/min, reduce volume and rate; monitor for electrolyte imbalances; consider avoidance in severe renal impairment.
For GFR <30 m L/min: reduce dose to 0.5-1 g/kg/day; monitor serum amino acids and nitrogen balance.
No specific Child-Pugh based adjustments; use with caution in severe hepatic encephalopathy; monitor ammonia levels.
Child-Pugh B or C: avoid standard formulations; use branched-chain amino acid (BCAA)-enriched solutions at 0.8-1.2 g/kg/day.
Dose based on weight: 2 to 6 g/kg/day of amino acids and 15 g/kg/day of dextrose; start at 2 g/kg/day of amino acids and titrate; typical infusion rate 100-200 m L/kg/day.
0.5-2 g/kg/day IV; titrate based on age, growth, and metabolic needs.
Start at lower infusion rates (e.g., 100 m L/hour); monitor fluid balance, renal function, and electrolytes; reduce total volume to avoid fluid overload.
Initiate at 0.8 g/kg/day IV, adjust based on renal function and nitrogen balance; monitor for fluid overload.
None
Patients receiving amino acid infusions should be monitored for metabolic acidosis, hyperammonemia, and renal function impairment. Solutions with electrolytes should not be used in patients with severe electrolyte imbalances.
Do not administer if solution is discolored or contains particulate matter,Use with caution in patients with renal impairment, hepatic failure, or metabolic disorders,Monitor fluid and electrolyte balance, blood glucose, and acid-base status,Risk of infections related to catheter use,Rebound hypoglycemia may occur upon abrupt discontinuation
Use with caution in patients with renal impairment, hepatic failure, heart failure, or metabolic acidosis. Monitor serum electrolytes, blood urea nitrogen, and ammonia levels. Avoid rapid infusion to prevent hyperosmolarity and venous thrombosis.
Hypersensitivity to any component,Inborn errors of amino acid metabolism,Severe hyperglycemia or hyperosmolar state,Severe electrolyte disturbances,Severe hepatic or renal failure
Hypersensitivity to any component, inborn errors of amino acid metabolism (e.g., phenylketonuria) without specific formula, severe hyperammonemia, anuria, or metabolic acidosis.
No oral intake restrictions specific to this formulation as it is for parenteral use. However, if transitioning to oral feeding, coordinate with dietitian to avoid electrolyte imbalances or overfeeding.
No significant food interactions; however, enteral nutrition should be managed to avoid excessive protein intake. Patients with phenylketonuria must avoid phenylalanine-containing amino acid solutions.
No expected increase in fetal malformation risk; amino acids and dextrose are endogenous nutrients. However, electrolyte disturbances or hyperglycemia may occur and can affect fetal development. First trimester: theoretical risk from metabolic derangements. Second and third trimesters: fetal growth and metabolic monitoring recommended.
Amino acids are essential nutrients; at physiologic doses, no teratogenic risk is established. At supraphysiologic doses, theoretical risk of metabolic imbalance exists. No trimester-specific human data; animal studies show no teratogenicity at standard doses.
Components are normal blood constituents and are transferred into breast milk in small amounts. Not expected to cause adverse effects in breastfed infants. M/P ratio not established.
Amino acids are normal constituents of breast milk; supplementation likely results in increased maternal levels but endogenous secretion maintains relatively constant milk levels. M/P ratio not established; generally considered compatible with breastfeeding at recommended doses.
Increased plasma volume and renal clearance in pregnancy may necessitate higher infusion rates to maintain adequate nutrition; individualize based on clinical response and laboratory parameters.
No specific dose adjustments required for enteral amino acids. For parenteral nutrition, consider increased requirements in third trimester (protein needs up to 1.5 g/kg/day). Adjust based on maternal weight gain, renal function, and metabolic monitoring.
TRAVASOL 4.25% IN DEXTROSE 15% is a high-osmolarity parenteral nutrition solution (approximately 1700 m Osm/L). Must be administered via central venous line to avoid thrombophlebitis. Monitor serum glucose, electrolytes, renal function, and liver enzymes frequently. Risk of hyperglycemia, especially in stressed patients; consider insulin coverage. Do not use as a peripheral line solution due to high osmolarity.
Amino acid infusions should be administered via central line if osmolarity > 900 m Osm/L to prevent thrombophlebitis. Monitor serum ammonia and BUN in patients with hepatic or renal impairment. Use with caution in patients with inborn errors of amino acid metabolism.
This solution is given through a large vein in your chest, not a small vein in your arm.,You may need regular blood tests to check your blood sugar, kidney function, and mineral levels.,Report any signs of infection at the catheter site, such as redness, swelling, or pain.,Tell your healthcare provider if you feel unusually thirsty, urinate frequently, or have blurred vision.,Do not stop the infusion suddenly without medical advice.
This medication provides essential building blocks for protein synthesis.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing.,Inform your doctor if you have liver or kidney disease.,Do not take other protein supplements unless directed by your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER vs AMINO ACIDS, answered by our medical review team.
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by Travasol 4.25% in Dextrose 15% is a combination of amino acids and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis, while dextrose provides a source of calories. The mechanism involves intravenous administration bypassing the gastrointestinal tract to deliver nutrients directly into the bloodstream, supporting tissue repair, growth, and metabolic functions.. AMINO ACIDS is a Parenteral Nutrition Solution that works by Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER and AMINO ACIDS depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 500 m L to 1000 m L per day, administered at a rate of 200 m L/hour, adjusted based on metabolic and fluid needs.. The standard adult dose of AMINO ACIDS is: 1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER and AMINO ACIDS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER is classified as Category C. No expected increase in fetal malformation risk; amino acids and dextrose are endogenous nutrients. However, electrolyte disturbances or hyperglycemia may occur and can affect feta. AMINO ACIDS is classified as Category C. Amino acids are essential nutrients; at physiologic doses, no teratogenic risk is established. At supraphysiologic doses, theoretical risk of metabolic imbalance exists. No trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.